IBRX Jumps After FDA Accepts ANKTIVA sBLA For NMIBCThe FDA has accepted ImmunityBio’s sBLA for ANKTIVA, which is aimed at expanding treatment options for patients with BCG-unresponsive NMIBC.The FDA assigned a PDUFA target action date of Jan. 6, 2027, indicating a significant step forward for the company’s product pipeline.The supplemental application is supported by data from the QUILT 3.032 Phase 2/3 trial in 80 patients. The study met its primary endpoint with a 12-month disease-free survival (DFS) rate of 58.2%.ANKTIVA plus BCG with BCG unresponsive non-muscle invasive bladder cancer and papillary disease alone demonstrated:How ImmunityBio (IBRX) Ranks On Momentum And PerformanceBelow is the Benzinga Edge scorecard for ImmunityBio, highlighting its strengths and weaknesses compared to the broader market:
Momentum: Bullish (Score: 98.15) — Stock is outperforming the broader market.
